Stevanato (STVN) reported Q4 adjusted earnings Wednesday of 0.18 euro per diluted share, down from 0.19 euros a year earlier.

Analysts polled by FactSet expected 0.17 euro.

Revenue for the quarter ended Dec. 31 was 346.5 million euros, up from 330.6 million euros a year earlier.

Analysts surveyed by FactSet expected 333.1 million euros.

For 2026, the pharmaceutical services and supply company expects adjusted EPS of 0.59 euro to 0.63 euro and revenue of 1.26 billion euros to 1.29 billion euros.

Analysts surveyed by FactSet expect 0.63 euro and 1.28 billion euros, respectively.

Shares of the company were up 5.1% in recent premarket activity.